GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lucy Scientific Discovery Inc (NAS:LSDI) » Definitions » EV-to-EBITDA

Lucy Scientific Discovery (Lucy Scientific Discovery) EV-to-EBITDA : -0.39 (As of May. 12, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Lucy Scientific Discovery EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Lucy Scientific Discovery's enterprise value is $3.29 Mil. Lucy Scientific Discovery's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.38 Mil. Therefore, Lucy Scientific Discovery's EV-to-EBITDA for today is -0.39.

The historical rank and industry rank for Lucy Scientific Discovery's EV-to-EBITDA or its related term are showing as below:

LSDI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -3.07   Med: -0.81   Max: -0.39
Current: -0.39

During the past 3 years, the highest EV-to-EBITDA of Lucy Scientific Discovery was -0.39. The lowest was -3.07. And the median was -0.81.

LSDI's EV-to-EBITDA is ranked worse than
100% of 708 companies
in the Drug Manufacturers industry
Industry Median: 14.76 vs LSDI: -0.39

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-12), Lucy Scientific Discovery's stock price is $0.73. Lucy Scientific Discovery's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.084. Therefore, Lucy Scientific Discovery's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Lucy Scientific Discovery EV-to-EBITDA Historical Data

The historical data trend for Lucy Scientific Discovery's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lucy Scientific Discovery EV-to-EBITDA Chart

Lucy Scientific Discovery Annual Data
Trend Jun21 Jun22 Jun23
EV-to-EBITDA
- - -2.92

Lucy Scientific Discovery Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - -3.03 -2.92 -1.64 -0.78

Competitive Comparison of Lucy Scientific Discovery's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Lucy Scientific Discovery's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lucy Scientific Discovery's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lucy Scientific Discovery's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Lucy Scientific Discovery's EV-to-EBITDA falls into.



Lucy Scientific Discovery EV-to-EBITDA Calculation

Lucy Scientific Discovery's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=3.290/-8.379
=-0.39

Lucy Scientific Discovery's current Enterprise Value is $3.29 Mil.
Lucy Scientific Discovery's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.38 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lucy Scientific Discovery  (NAS:LSDI) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Lucy Scientific Discovery's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.73/-7.084
=At Loss

Lucy Scientific Discovery's share price for today is $0.73.
Lucy Scientific Discovery's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.084.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Lucy Scientific Discovery EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Lucy Scientific Discovery's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Lucy Scientific Discovery (Lucy Scientific Discovery) Business Description

Traded in Other Exchanges
N/A
Address
301-1321 Blanshard Street, Victoria, BC, CAN, V8W 0B6
Lucy Scientific Discovery Inc is an early-stage psychotropics contract manufacturing company focused on becoming the contract research, development, and manufacturing organization for the emerging psychotropics-based medicines industry. Its drug products are designed to treat a range of mental health and cognitive conditions.
Executives
Richard D Nanula director, officer: Executive Chairman C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Charles B Nemeroff director C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Paul Abramowitz director C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Brian Zasitko officer: Chief Financial Officer C/O LUCY SCIENTIFIC DISCOVERY, INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Scott M. Reeves director C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Christopher Mcelvany director, officer: President and CEO C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Livio Susin director C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Brittany Kaiser director C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Assad J Kazeminy officer: Chief Scientific Officer C/O LUCY SCIENTIFIC, INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6

Lucy Scientific Discovery (Lucy Scientific Discovery) Headlines